Pharmaceutical

ITM targets US approval for radiopharmaceutical after Phase III readout

The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.

Mar 7, 2025 - 06:00
ITM targets US approval for radiopharmaceutical after Phase III readout
The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.
Read the original article

Tags:

Previous Article

Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

Next Article

Project Optimus: The evolution of dose optimisation in oncology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Now 18, the first child to ever receive CAR-T cancer therapy is ready for a new identity

Now 18, the first child to ever receive CAR-T cancer th...

May 3, 2023

STAT+: Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

STAT+: Medicare eyes cuts to doctors, raises to outpati...

Jul 14, 2023

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

FDA expands Pfizer’s RSV vaccine label to include all h...

Oct 24, 2024